New primary monoclonal antibodies
Synabs announces a large Horizon European grant for the generation of therapeutic antibodies on transmembrane targets and highly conserved soluble proteins
SYnAbs monoclonals specific to glucagon without cross-reaction to GLP-1, Glicentin, Oxyntomodulin and Proglucagon, to diagnose diabetes and glucagonomas diseases
SYnAbs unique monoclonal antibodies are highly specific to hemoglobin mutations HbA, HbC, HbE, HbS, and pan-Hb to detect sickle cell disease.
Benefit from natural in-vivo maturation to get access to highly specific and high affinity rat monoclonal antibodies for therapeutic use targeting transmembrane proteins GPCR, ion channels and other complex epitopes
SYnAbs has developed IL-1β monoclonal antibodies and immunoassays (ELISA and ELISpot kits) to help you monitor the immune responses to diverse infections,
diagnose auto-inflammatory diseases,
and simply get the best out of your inflammation research.
SYnabs develops surrogate antibodies for preclinical evaluation of therapeutic antibody candidates in mouse, rat, and guinea pig species.
Synabs unique anti-KIAA1199, anti-CEMIP, anti-Hybid monoclonal antibody
Synabs launches anti-pan-SERPin and anti-SERPinA monoclonal antibodies. 3,000 members. Complicated family reunions to organize. And unfortunately, not as famous as the Kardashians. Meet the SERPin family and SYnabs unique products.
Adeno-associated virus (AAV) is a small and single strand DNA virus. In 1960, this non-enveloped entity was accidentally discovered in adenovirus culture. It was before we understood that AAV requires the presence of another "helper" virus in order to propagate. This family was named as “Dependovirus genus”.
SYnAbs unique anti-His tag monoclonal antibodies for detection of any recombinant protein. Primary antibodies.